Preliminary evaluation of urinary soluble Met as a Biomarker for urothelial carcinoma of the bladder Academic Article uri icon

Overview

MeSH Major

  • Biomarkers, Tumor
  • Proto-Oncogene Proteins c-met
  • Urinary Bladder Neoplasms
  • Urothelium

abstract

  • Urinary sMet levels distinguish patients with BCa from those without, and patients with or without MIBCa, suggesting the potential utility of urinary sMet as a BCa biomarker for surveillance following initial treatment. Further studies are warranted to determine its potential value for prognosis in advanced disease, predicting treatment response, or identifying patients likely to benefit from Met-targeted therapies.

publication date

  • October 21, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4283116

Digital Object Identifier (DOI)

  • 10.1186/1479-5876-12-199

PubMed ID

  • 25335552

Additional Document Info

start page

  • 199

volume

  • 12

number

  • 1